Dermatitis clinical trials

The registry lists 238 studies for Dermatitis across more than 10 countries. 34 are recruiting or about to start. 71 of them are mainly about Dermatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 11 narrower conditions too, such as Dermatitis, Atopic: 2,274 studies, 389 open.

Get an email when these change. Save the Dermatitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 138
Recruiting: 23
Terminated: 22
Status unknown: 18
Active, not recruiting: 15
Withdrawn: 11

Phase

Phase 3: 50
Phase 2: 49
Phase 1: 28
Phase 4: 15
Early Phase 1: 3

Where

United States: 110
Canada: 44
Germany: 42
France: 30
Poland: 29
Spain: 28

Who runs them

Novartis Pharmaceuticals (16) · Pfizer (9) · GlaxoSmithKline (7) · Eli Lilly and Company (6) · Incyte Corporation (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Organon and Co (4) · Almirall, S.A. (4)

What is being tested here

Drugs under test in Dermatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Lebrikizumab	2	10	11
IMG-007	2	0	3
Tilrekimig	2	2	2
Tacrolimus	1	0	3
Abrocitinib	1	3	3
Camoteskimab	1	0	2
Roflumilast	1	1	2
Doxycycline	1	0	1
AB-101	1	0	1
Secukinumab	0	7	9

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · JAK inhibitors 1 open · Calcineurin inhibitors 1 open · Corticosteroids 10 · Antihistamines 6

Coming up

10phase 3 studies under way

16studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 3 · Wei-Che Ko
Apr 2027A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · Almirall, S.A.
May 2027A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema · Phase 3 · Pfizer
May 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) · Phase 3 · Novartis Pharmaceuticals
Jun 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Novartis Pharmaceuticals
Nov 2026Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks · Pierre Fabre Dermo Cosmetique
Nov 2026A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks · Foundation University Islamabad
Nov 2026Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience · IRCCS San Raffaele
Dec 2026Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota · SCF Pharma
Jan 2027Effects of Treatments on Atopic Dermatitis · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Who these studies take

Of the 23 Dermatitis studies recruiting now, 11 (48%) set no upper age limit and 9 (39%) stop at 75 or younger. 12 (52%) take children under 18. 2 (9%) are for women only and 0 (0%) for men only; 4 (17%) take healthy volunteers.

Recruiting studies that take each age, of 23
Age	Women	Men
10	8 (35%)	8 (35%)
18	20 (87%)	19 (83%)
30	21 (91%)	20 (87%)
40	22 (96%)	20 (87%)
50	21 (91%)	19 (83%)
65	19 (83%)	18 (78%)
75	15 (65%)	14 (61%)
85	14 (61%)	13 (57%)

Across all 238 studies, recruiting or not: 42% stop at 75 or younger and 32% at 65; 30% take children; 8% are for women only and 3% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dermatitis studies take

Of 29 phase 3 interventional studies under Dermatitis, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	10 mo6–24 · 13 studies	—	—
Phase 2	22 mo10–53 · 20 studies	—	—
Phase 3	20 mo16–35 · 29 studies	20 mo13–28 · 28 studies	—
Interventional, no phase	8 mo3–13 · 36 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting1

Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNov 6, 2026NCT07916480

Newly registered2

Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNov 4, 2026NCT07916480
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other TherapiesOct 21, 2026NCT07887867

Studies

Recruiting first, then most recently updated. Showing 50 of 238. Browse all 238 → or search them.